about
BRAF mutation in progression and therapy of melanoma, papillary thyroid carcinoma and colorectal adenocarcinomaDacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalitiesAspirin--the prodigious panacea? Molecular mechanisms of the action of acetylsalicylic acid in the organismIncreased protein glycation in diabetes mellitus is associated with decreased aspirin-mediated protein acetylation and reduced sensitivity of blood platelets to aspirinElevated cholesterol reduces acetylsalicylic acid-mediated platelet acetylationPentoxifylline Inhibits WNT Signalling in β-Cateninhigh Patient-Derived Melanoma Cell PopulationsTranscription factors as targets of anticancer drugs.Parthenolide, a sesquiterpene lactone from the medical herb feverfew, shows anticancer activity against human melanoma cells in vitro.Transcription factors as targets for DNA-interacting drugs.Natural compounds' activity against cancer stem-like or fast-cycling melanoma cells.Gene expression profiling identifies microphthalmia-associated transcription factor (MITF) and Dickkopf-1 (DKK1) as regulators of microenvironment-driven alterations in melanoma phenotypeMITF in melanoma: mechanisms behind its expression and activity.MCL-1, BCL-XL and MITF Are Diversely Employed in Adaptive Response of Melanoma Cells to Changes in Microenvironment.Effects of anticancer drugs on transcription factor-DNA interactions.Parthenolide reduces the frequency of ABCB5-positive cells and clonogenic capacity of melanoma cells from anchorage independent melanospheres.Parthenolide induces MITF-M downregulation and senescence in patient-derived MITF-M(high) melanoma cell populationsPARP1 inhibitor olaparib (Lynparza) exerts synthetic lethal effect against ligase 4-deficient melanomas.Proteomics in human cancer research.Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II.Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part I.Pro-apoptotic activity of BH3-only proteins and BH3 mimetics: from theory to potential cancer therapy.Anti-apoptotic proteins on guard of melanoma cell survival.Pro-survival role of MITF in melanoma.Accumulation of gamma-globin mRNA and induction of irreversible erythroid differentiation after treatment of CML cell line K562 with new doxorubicin derivatives.Autoregulation of GAL4 transcription is essential for rapid growth of Kluyveromyces lactis on lactose and galactose.Selective Sp1 and Sp3 binding is crucial for activity of the integrin alphaV promoter in cultured endothelial cells.Inhibition of RNA synthesis in vitro by acridines--relation between structure and activity.Modulation of WNT/β-catenin pathway in melanoma by biologically active components derived from plants.The synthesis, lipophilicity and cytotoxic effects of new ruthenium(II) arene complexes with chromone derivatives.Diminution of miR-340-5p levels is responsible for increased expression of ABCB5 in melanoma cells under oxygen-deprived conditions.Expression of miRNAs as Important Element of Melanoma Cell Plasticity in Response to Microenvironmental Stimuli.miRNAs in Melanoma: Tumor Suppressors and Oncogenes with Prognostic Potential.Synthesis, physico-chemical properties and biological analysis of newly obtained copper(II) complexes with pyrazole derivatives.Parthenolide complements the cell death-inducing activity of doxorubicin in melanoma cells.Parthenolide enhances dacarbazine activity against melanoma cells.Synthesis and biological evaluation of new bischromone derivatives with antiproliferative activity.Copper(II) complexes with derivatives of pyrazole as potential antioxidant enzyme mimics.Synthesis and in vitro biological evaluation of new polyamine conjugates as potential anticancer drugs.Cell context-dependent activities of parthenolide in primary and metastatic melanoma cellsTautomerization of 2-nitroso-N-arylanilines by coordination as N,N'-chelate ligands to rhenium(I) complexes and the anticancer activity of newly synthesized oximine rhenium(I) complexes against human melanoma and leukemia cells in vitro.
P50
Q26749502-110FC79E-05F0-4B8F-893E-517FE3EF8801Q26827205-28C5CA4C-5E54-47BC-811A-5959206ED062Q28176301-D6150A14-0528-47AB-810E-187BFC7174AFQ28217950-0905FAF1-2B1A-4B50-BC06-7EC6EE0A5061Q28222951-EFE4C6DA-E9E5-4273-B4C4-BF93C1AF55DBQ28552213-CF3D63F1-D704-4188-8A71-4BA16ADFCAF3Q33765504-CDE103DB-EFB5-422B-990F-7B03E99C54FEQ35015251-FDE02B25-4DFE-40DE-A8EB-66C8DC530211Q35100339-0BA40C62-567E-44DE-B910-3D34ECE667CEQ35111429-DB925BFD-0A15-48AB-AAE8-8398410F97CEQ35147858-01159EFD-386E-4173-A652-FCEDDC1CCD11Q35187734-118E1523-260C-4C3D-A36B-8A4599F6015EQ35650051-00B4A272-228F-4762-9C32-1C81F8FA92D3Q36158697-9D92370D-022F-4C20-8A06-A8845E3284EDQ36608707-E86B6BD9-8A4D-47EF-A447-B1921542141BQ36962495-9C77FD0D-CBC6-471D-A067-F0FFCA3B3630Q37688982-0FA18C2D-A952-4974-BD03-72B361AC940AQ37817081-B6438198-EBDA-45DD-A7FC-E9CE14A7DB5EQ37882456-871B1E1E-9148-440C-BF4C-F784EF4A63CEQ37882459-9BDDF715-48E4-4679-AF65-10704D11A8DBQ37977487-9C2547B1-47D2-4A0C-9CB2-C3C9617DBFB0Q38075980-0EEEDFF4-EEA9-4160-AF18-163B57CE3618Q38241749-2E162157-513A-4C9C-86B6-72E7C6AF5C13Q38307724-2BFE06B6-DA89-4563-AA1B-0FDD5B19EE5CQ38316123-BC22531B-A466-47E3-8417-11B9099931D9Q38320011-69397604-4BFA-4641-AE1E-FEFA713764B7Q38335209-FF0F8011-41EF-4DB3-B18F-61C3AB1A67FDQ38724731-E3DB98D9-1A5F-4365-93A4-AB8483CF8192Q38785490-3AECA179-FC3A-4B44-8AA3-32CFC3785AD7Q38820477-B7B19489-9813-4E01-9889-B33F2FA9FD9EQ38876125-D6E5DC32-AB27-4747-9C04-DE077D598237Q38964180-8FA0350C-701D-4954-98B3-B54F351088FFQ39012352-3EEDC212-314D-48D4-959E-15BD66A9A0E5Q39118229-343BA8D8-938E-41DB-BAC4-82ACC4F3A580Q39135558-1918A6D3-B33F-434A-A3DF-1F003F886A64Q39251773-708FA0A9-3127-4A32-8165-4ACE7828D1ADQ39324610-D1FD36F6-2EBB-4D1B-9F7F-643FEA297AC8Q39640112-2963EF41-61A8-40E9-856B-32C070D21B96Q39686730-D50D37E3-8B25-428D-80B9-F766CD75F454Q39710669-4BFF656E-3DB6-44B2-97EF-689587B3E7F5
P50
description
Pools onderzoekster
@nl
hulumtuese
@sq
polska biolog molekularna
@pl
researcher
@en
ricercatrice
@it
հետազոտող
@hy
name
Malgorzata Czyz
@ast
Malgorzata Czyz
@en
Malgorzata Czyz
@es
Malgorzata Czyz
@nl
Malgorzata Czyz
@sl
Małgorzata Czyż
@ca
Małgorzata Czyż
@cs
Małgorzata Czyż
@gl
Małgorzata Czyż
@hr
Małgorzata Czyż
@hsb
type
label
Malgorzata Czyz
@ast
Malgorzata Czyz
@en
Malgorzata Czyz
@es
Malgorzata Czyz
@nl
Malgorzata Czyz
@sl
Małgorzata Czyż
@ca
Małgorzata Czyż
@cs
Małgorzata Czyż
@gl
Małgorzata Czyż
@hr
Małgorzata Czyż
@hsb
altLabel
Małgorzata Ewa Czyż
@pl
prefLabel
Malgorzata Czyz
@ast
Malgorzata Czyz
@en
Malgorzata Czyz
@es
Malgorzata Czyz
@nl
Malgorzata Czyz
@sl
Małgorzata Czyż
@ca
Małgorzata Czyż
@cs
Małgorzata Czyż
@gl
Małgorzata Czyż
@hr
Małgorzata Czyż
@hsb
P214
P1153
6603799220
P1412
P1559
Małgorzata Czyż
@pl
P21
P213
0000 0001 1433 6312
P214
P27
P31
P3124
P496
0000-0002-8279-4742
P7293
9810688200705606
P734
P735
P7859
viaf-167346135